Results 261 to 270 of about 199,032 (289)
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Cancers, 2021 Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells.
Walid Shalata +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Immune checkpoint inhibitors in GBM
Journal of Neuro-Oncology, 2021The purpose of this review is to summarize recent updates regarding immune checkpoint inhibitor therapy in GBM patients including updates in brain immunology, clinical trials, mechanisms of resistance, and biomarkers of response.PubMed was searched to identify recent relevant articles on immune checkpoint inhibitor therapy as it pertains to GBM ...
openaire +2 more sources
Immune Checkpoint Inhibitor Toxicity
Current Oncology Reports, 2018Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges ...
David J, Palmieri, Matteo S, Carlino
openaire +2 more sources
Cardiotoxicity of Immune Checkpoint Inhibitors
Current Treatment Options in Cardiovascular Medicine, 2019Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang +8 more
openaire +2 more sources
Immune checkpoint inhibitor myocarditis
Current Opinion in Cardiology, 2019The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire +2 more sources
Radiotherapy, immunity, and immune checkpoint inhibitors
The Lancet OncologyRadiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune checkpoint inhibitors, multiple clinical trials were initiated with the hypothesis that combined
Connor, Lynch +2 more
openaire +2 more sources
Melanoma and Immune Checkpoint Inhibitors
Current Oncology Reports, 2018Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8Â months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue +5 more
openaire +2 more sources
Immune Checkpoint Inhibitors in Cholangiocarcinoma
Immunotherapy, 2023Cholangiocarcinoma is an epithelial malignancy originating in the biliary tracts and frequently recurs even with surgical resection. Unresectable disease has a 5-year overall survival of less than 10%. Given this poor prognosis, additional therapies are urgently needed. Chemotherapy has been the mainstay of treatment for many years.
openaire +2 more sources
Immune Checkpoint Inhibitor–Induced Lipodystrophy
JAMA DermatologyThis case series describes lipodystrophy, a rare adverse event associated with immune checkpoint inhibitor therapy.
Riganti J. +15 more
openaire +3 more sources